School of Medicine
Showing 1-3 of 3 Results
Sri-Rajasekhar (Raj) Kothapalli, PhD
Instructor, Radiology- Molecular Imaging Program at Stanford
Current Research and Scholarly Interests My current research is focused on developing non-ionizing and low cost medical technologies that reliably detect the disease and also capable of predicting the prognosis. Towards this goal, I work at the interface of Photonics, Acoustics, MEMS, Molecular Imaging, Medical Imaging and Computing. Equal emphasis is on translating these technologies for pre-clinical and clinical applications in cancer and neurological diseases.
At Stanford, I invented a transrectal ultrasound and photoacoustic (TRUSPA) device for imaging human prostate using capacitive micromachined ultrasonic transducer (CMUT) array technology. Pilot clinical studies on prostate cancer patients demonstrated that the device is capable of simultaneously displaying anatomical and molecular information of the prostate. Currently, relevant molecular imaging approaches are being investigated to further improve the sensitivity and the specificity of the prostate cancer detection. Similarly, I also developed an intra-operative ultrasound and photoacoustic (iUSPA) device that is in the path to clinical translation for various applications.
My other research interests include Cerenkov luminescence imaging, and developing novel microscopy and in vitro diagnostic techniques for probing complex cell signaling pathways.
Shivaani Kummar, MD, FACP
Professor of Medicine (Oncology) and of Radiology (Molecular Imaging Program at Stanford) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Kummar’s research interests focus on developing novel therapies for cancer. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. Her studies integrate genomics and laboratory correlates into early phase trials. She is interested in alternate trial designs to facilitate rational drug selection based on human data and help expedite drug development timelines. She has published numerous articles in medical journals and serves on a number of national and international scientific committees.